Trials / Unknown
UnknownNCT01988740
Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (estimated)
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital · Other Government
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The finding that ischemia-modified albumin (IMA) is increased in pre-eclamptic pregnancy suggests a role for IMA as a potential biomarker for abnormal placental development related to miscarriage.This study was undertaken to evaluate IMA levels in women with recurrent pregnancy loss (RPL).
Detailed description
Ischemia-modified albumin (IMA) measured by the albumin cobalt binding test is a relatively new biomarker in the identification of myocardial ischemia. Experimental studies have shown that pregnancies normally develop in a relatively hypoxic intrauterine environment, and the subsequent reperfusion and oxidative stress is important for physiological trophoblast development. The finding that maternal serum IMA levels are raised so early in pregnancy provides further support for IMA as a potential marker for abnormal placental development that may be related to early pregnancy loss. In this study, we aimed to evaluate maternal circulating IMA levels in women with RPL by comparing them with healthy controls.
Conditions
- First Trimester Pregnancy
- Fetal Heart Activity Absent
- Absence of Fetal Pole on Ultrasonographic Examination.
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2014-03-01
- Completion
- 2014-04-01
- First posted
- 2013-11-20
- Last updated
- 2013-11-20
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01988740. Inclusion in this directory is not an endorsement.